AbbVie May Not Get All of Allergan for Antitrust Reasons, Argus Analyst Toung Says

The transcript discusses a business deal involving Bristol Myers and Celgene, highlighting potential trust issues and market reactions. It explores the strategic decisions and challenges faced by Allegan, including clinical trial misfires and IP protection issues. The discussion also covers the future prospects of the deal, focusing on asset management and competition.

What is one of the main concerns regarding the business deal discussed in the first section?

• The potential for increased competition

• Antitrust issues and cost rationalization

• Lack of market interest

• Insufficient financial backing

What was one of the pressures faced by Allegan as mentioned in the second section?

• Misfires in clinical trials

• Successful clinical trials

• Excessive financial resources

• Overwhelming market demand

What strategic option was Allegan considering due to its business challenges?

• Expanding into new markets

• Being bought out or splitting up

• Increasing product prices

• Reducing workforce

Which asset of Allegan is considered valuable but faces competition?

• Ibuprofen

• Aspirin

• Botox

• Paracetamol

What is a potential outcome for some of Allegan's assets after the deal with AbbVie?

• They might be divested

• They will be merged with another company

• They will be discontinued

• They will all be retained